Clinical Trial

Mechanisms Underlying SGLT2i Kidney Effect in DKD Progression

Study acronym: PERSONALISEDKD
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
This is a multicentre and multi-national non-pharmacological, uncontrolled interventional study conducted in a clinical practice setting in DKD patients with CKD stages 1 to 3 with moderate or severe risk of renal function decline in chronic treatment with SGLT2i. The main aim of the study is to assess the independent role of baseline individual mpMRI markers (hemodynamic, oxygenation, microstructure, perfusion, and fat fraction) and biochemical markers of MMP-related pathways (MMP-10 and TIMP-1) in the prediction of chronic eGFR decline in the above mentioned patients who are on chronic SGLT2i therapy.
Trial Details
NCT Number NCT07270198
Lead Sponsor Mario Negri Institute for Pharmacological Research
Conditions Diabetic Kidney Disease (DKD)
Enrollment 100 participants
Start Date 2026-02
Primary Completion 2027-08 (estimated)
Study Completion 2027-08 (estimated)
Updated on ClinicalTrials.gov 2025-12-08